Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Mallinckrodt
McKinsey
Medtronic

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket   Start Trial Date Filed 2015-08-05
Court District Court, D. Delaware Date Terminated 2018-04-24
Cause 35:0145 Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACTAVIS LABORATORIES FL, INC.; ALVOGEN PINE BROOK INC.; ALVOGEN PINE BROOK LLC; GRUNENTHAL GMBH; PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P.; THE P.F. LABORATORIES INC.
Patents 6,011,020; 6,733,783; 8,114,383; 8,309,060; 8,361,499; 8,529,948; 8,551,520; 8,647,667; 8,808,740; 9,023,401; 9,056,052; 9,060,940; 9,084,816; 9,095,614; 9,095,615; 9,198,863; 9,205,056; 9,486,412; 9,486,413; 9,492,390; 9,492,391; 9,517,236; 9,545,380; 9,572,779; 9,572,804; 9,669,024; 9,675,610; 9,675,611; 9,750,703; 9,763,933; 9,775,809
Attorneys Aaron M. Nelson; Dominick T. Gattuso; Edward M. Mathias; Evan T. Lee; Gary E. Hood; Gasper J. LaRosa; Gita Srivastava; Graham L.W. Day; Jack B. Blumenfeld; James L. Higgins; Jason A. Wietjes; Jason G. Winchester; Jeffrey I.D. Lewis; Jenny Shum; Jeremy Lowe; John J. Normile; Joshua S. Reisberg; Kenneth S. Canfield; Khurram Naik; Lisamarie LoGiudice; Mark T. Deming; Matthew J. Becker; Megan Elizabeth Dellinger; Melanie K. Sharp; Michelle Wang; Nicholas J Doyle; Rebecca L. Clegg; Ricardo S. Camposanto; Robert M. Vrana; Rodger Dallery Smith , II; Sarah A. Geers; Stacie L. Ropka; Thomas G. Rohback
Firms Axinn, Veltrop & Harkrider, LLP; Heyman Enerio Gattuso & Hirzel LLP; Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Purdue Pharma L.P. v. Alvogen Pine Brook LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2017-04-18 175 Hossein Omidian Regarding Invalidity of U.S. Patent Nos. 6,733,783; 8,361,499; 8,551,520; 8,647,667; 9,023,…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware External link to document
2017-04-19 177 Jacobs, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Mayersohn, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Muzzio, Ph.D. Concerning the Invalidity of U.S. Patent Nos. 8,529,948; 8,309,060; 9,084,816; 9,095,614…Ryu, Ph.D. Concerning the Indefiniteness of U.S. Patent Nos. 9,198,863 and 8,808,740 filed by Alvogen Pine…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware External link to document
2017-05-10 178 cannot be easily pulverized or crushed. Id. col. 6 11. 20-23. The specification goes on to explain that ….S. Patent Nos. 6,733,783 ("the '783 patent"), 8,361,499 ("the '499 patent"…948 patent"), 8,808,740 ("the '740 patent"), 9,056,052 ("the '052 patent"…8,551,520 ("the '520 patent"), 8,647,667 ("the '667 patent"), 9,023,401 ("…quot;the '401 patent), 8,309,060 (''the '060 patent"), 8,529,948 ("the '948 External link to document
2015-10-13 18 owner of U.S. Patent Nos. 6,733,783 (“the ‘783 patent”), 8,361,499 (“the ‘499 patent”), 8,551,520 (“…U.S. Patent No. 8,529,948 (“the ‘948 patent). The ‘783 patent, the ‘499 patent, the ‘520 patent, the …the ‘667 patent, the ‘401 patent, the ‘948 patent, the ‘740 patent, and the ‘060 patent, collectively, …(“the ‘520 patent”), 8,647,667 (“the ‘667 patent”), 9,023,401 (“the ‘401 patent”), and 8,808,740 (“the…740 patent”), and that it is an exclusive licensee of U.S. Patent No. 8,309,060 (“the ‘060 patent”) ( External link to document
2017-06-06 184 Dave Regarding Non-Infringement of U.S. Patent Nos. 8,551,520; 8,647,667; 8,808,740; and 9,095,614 filed…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Express Scripts
Colorcon
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.